Ipsen revamps U.S. sales ops for new cancer push; Gilead taps Mylan to sell HIV meds in India; Noven signs up to market hot-flash drug Brisdelle;

>Ipsen is setting up its own U.S. oncology team to market Somatuline, an acromegaly treatment, for potential new cancer indications; the French drugmaker's CEO will personally oversee the effort, with the help of a newly hired chief of endocrinology and oncology, Cynthia Schwalm. Report

> Gilead Sciences ($GILD) signed up U.S.-based Mylan ($MYL) to market its HIV treatments Viread, Truvada, and Stribild in India, where the U.S.-based generics maker has been expanding production and marketing. Report

> Noven, the U.S. unit of Hisamitsu Pharmaceutical, signed on to co-promote Brisdelle, the recently approved remedy for hot flashes from Shionogi. Report

> ViiV Healthcare, the HIV-oriented joint venture between GlaxoSmithKline ($GSK) and Pfizer ($PFE), launched its new drug Tivicay in the U.K.; it lacks public funding there yet, so for now it's available via private prescription. Report

> New guidances expected this year from the FDA and the HHS Office of Inspector General stand to affect both drug marketing and research. Report

> Biogen Idec ($BIIB) will be gearing up to launch its multiple sclerosis drug in Europe now that regulators there have approved the treatment. Report

> U.K. regulators green-lighted Allergan's ($AGN) Botox injection to treat ankle disability in stroke patients. Report

And Finally... Do patients want biopharma to be part of their social media conversations? Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.